

INTRODUCING NEW CAP MEMBERS

AACE is pleased to announce the following new CAP members:

Apricus Biosciences, Inc. – Apricus Biosciences specializes in the development and commercialization of innovative products in urology and rheumatology that provide life-improving treatments to patients.

Interpace Diagnostics – Interpace Diagnostics provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management.

AACE/ACE Scientific and Clinical Review of DKA and The Effects of SGLT2 Inhibitors

AACE will convene a conference of U.S. and international experts to examine the issue of diabetic ketoacidosis (DKA) among patients treated with SGLT2 inhibitors. AACE will conduct this meeting to provide answers to questions from its membership raised in response to recent case reports and publications on the subject. The **AACE/ACE Scientific and Clinical Review of DKA and The Effects of SGLT2 Inhibitors** is scheduled to take place October 24-25, 2015 at the Grand Hyatt DFW in Dallas, TX and will assemble top scientists, diabetes experts and relevant stakeholders in the diabetes care arena to examine available data and provide recommendations for prescribers and patients. For more information contact Glenn Sebold at gsebold@ace.com.

*****Mark your calendars for the 2015 Fall CAP Meeting to be held on
Friday, October 16, 2015, at the
Hyatt Regency Capitol Hill in Washington, DC!*****



Launched in 2013, the CAP Alert serves as an informational brief to AACE's corporate partners. The email alerts are managed by the AACE Business Development & Marketing Department. For more information, contact Edith Dix @ edix@ace.com

CAP MISSION: To facilitate the improvement of endocrine patient care by working with industry in areas of mutual interest.